Alkermes plc. Deferred Tax Liabilities, Property, Plant and Equipment
Alkermes plc. (ALKS) had Deferred Tax Liabilities, Property, Plant and Equipment of $46.27 million as of 2022-12-31, per its 10-K filed 2023-02-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment · last filed 2023-02-16
- 2022-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $46.27M.
- 2021-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $50.19M.
- 2020-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $52.71M.
- 2019-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $19.93M.
| Period end | Deferred Tax Liabilities, Property, Plant and Equipment |
|---|---|
| 2022-12-31 | $46.27M 10-K · filed 2023-02-16 |
| 2021-12-31 | $50.19M 10-K · filed 2023-02-16 |
| 2020-12-31 | $52.71M 10-K · filed 2022-02-16 |
| 2019-12-31 | $19.93M 10-K · filed 2021-02-11 |
| 2018-12-31 | $14.53M 10-K · filed 2020-02-13 |
| 2017-12-31 | $12.04M 10-K · filed 2019-02-15 |
| 2016-12-31 | $17.54M 10-K · filed 2018-02-16 |
| 2015-12-31 | $15.22M 10-K · filed 2017-02-17 |
| 2014-12-31 | $21.92M 10-K · filed 2016-02-25 |
| 2013-12-31 | $21.57M 10-K · filed 2015-02-24 |
| 2013-03-31 | $19.61M 10-KT · filed 2014-02-27 |
| 2012-03-31 | $19.05M 10-K · filed 2013-05-23 |
| 2011-03-31 | $6.48M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |